William Joseph Radvak

William Joseph Radvak discloses dealings in NervGen Pharma Corp. to SEDI. We count 9 filings; the first trade dates from 19 January 2017 and the latest from 28 March 2024.

No open-market purchase appears, only 3 sales worth €21k. Outside the open market, there are 1 option exercise.

Most recently, on 29 March 2024, the filings show a transaction worth €32k in NervGen Pharma Corp. Filings reach the SEDI feed a median of 5 days after the trade. This delay matters because a trade only becomes useful information once it is public. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.